TEST:

Oncotype DX Breast Recurrence Score®Test

Impact of #HER2LOW expression in the #Oncotype DX RS in patients with operable hormone receptor positive early-stage #breastcancer @LauraSofiaMuno9 @MCristofanill @ASCO #ASCO23 (@CtcLaboratory)

Our @WCMBreastCenter @WCM_MeyerCancer #ASCO23 Abstracts. Stop by and say hello tomorrow morning! @eleonora_nicolo @LauraSofiaMuno9 @MCristofanill #InflammatoryBreastCancer #liquidbiopsy #ctDNA #HER2Low #Oncotype (@CtcLaboratory)

@ASCO Abstract # 575 'Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.' #ASCO23 @LauraSofiaMuno9 @eleonora_nicolo @eleniandreop @JeannineDonahue @MCristofanill @LANewmanMD @CiglerTessa (@CtcLaboratory)

Identifying Patterns and Barriers in #OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive #Breastcancer : Implications for Guidance and Reimbursement https://t.co/pnK0bjZZgN @ASCO @JCOOP_ASCO @DrHBurstein @PTarantinoMD @stolaney1 (@jamecancerdoc)

Great body of work! Neoadjuvant Oncotype is underutilized. pCR rates higher in RS high HR+ breast cancer nearly 20%. Also not sure why we resist neoadjuvant abraxane other than cost. #bcsm esults from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial https://t.co/Cf5O4DHUZJ (@drsarahsam)

2/ For example, we have seen with OncotypeDx in breast cancer that some patients do not benefit from chemotherapy and can safely omit it. Similarly, in RCC, VHL and accompanying mutations are associated with the risk of recurrence. @myESMO @yekeduz_emre @Uromigos @DrDanielHeng (@DrYukselUrun)

Dr. Saranya Chumsri discusses the effects of intrinsic subtypes and the 21-gene assay on recurrence risks in patients with early stage HER2+ breast cancer. @SaranyaChumsri @MayoClinic #SABCS22 Read and Share the Article Here: https://t.co/b1FnMutIJy (@oncologytube)

Dr. Saranya Chumsri discusses the effects of intrinsic subtypes and the 21-gene assay on recurrence risks in patients with early stage HER2+ breast cancer. @SaranyaChumsri @MayoClinic #SABCS22 Watch and Share the Video Here: https://t.co/D8ORg6vVeu (@oncologytube)

Oh boy. I had a feeling you’d say this. Wonder what others in the field of young breast cancer think because in the US oncotypes under 40 are ordered and followed without a second thought. @hoperugo @KalinskyKevin @ErikaHamilton9 @DrSGraff @DrLisaCarey @AnnPartridgeMD ()

I was stage 2 IDC with low Oncotype. Nothing in my lymph nodes. I was told chemo wouldn’t make any difference for me. Did my 5 years of tamoxifen/Anastrozole and here I am #mbc 8 years later. Mine was the “easy” breast cancer. ()

Deep Onc thoughts on a Friday night: #bcsm friends when u see a young person who had a low #Oncotype develop #mbc what do u feel? Did they really fall in the 10% (again) or have we underestimated premenopausal breast cancer? ()

Low neighborhood-level household income was an independent prognostic factor for higher 21-gene recurrence score (RS) and worse survival outcome among women with ER+ breast cancer with RS <26. https://t.co/0PJLbAlFeu @SungJunMa @Single_Fx_Singh @RoswellPark ()

I just had surgery for breast cancer two days ago and I am now waiting on my Oncotype score. 🤞🏽 ()

Even with a low Oncotype I do not trust breast cancer in extremely young patients! It’s a nasty disease whether it is #tnbc , #her2+ or #HR+ #bcsm You must be vigilant in this disease! ()

Except racism leads to changes in biology. Even high exposure to soy products significantly changes Oncotype RS for breast cancer. No need to argue but no real data presented. You are trying to thread points together. No study was done. ()

Lest everyone think we are just interested in tailoring RT recs for #breastcancer, excited for another publication this month, this time exploring SET 2,3 index, Oncotype, and benefit from endocrine and systemic therapy benefit in N+ BC patients. https://t.co/SVbHcAFlss ()

47 yr old premenopausal lady,post BCS, T1(2.3cm),No,Mo.Lobular Ca Gr1,Ki 7%,LuminalA type One Margin positive . You would advise further (Oncotype DX not possible) #MedTwitter #predictbreast #breastcancer #radtwitter ()

Dr. Sherry Yang @NIH discussing Phase 3 #TAILORx #breastcancer Trial: 21-Gene Recurrence Score and OS from #SABCS22 #bcsm #VuMedi #OncTwitter #MedTwitter w/@jsparano @MountSinaiNYC https://t.co/dbsEQos70W ()

Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer https://t.co/I1CPuwZA8E #bcsm #breastcancer #SABCS2022 #SABCS22 #oncology @DrLisaCarey @drivorymd @UNC ()

#Oncotype DX® test portfolio. After a day full of #SABCS22 education and learnings, a view of Texas at night is just remarkable. Enjoy! #BreastCancer #PrecisionOncology #SABCS2022 ()

Comparison of #OncotypeDx vs Genomic Platform based on RNA StemCells in early breast cancer results at 5 and 10 years taking into account epigenetics. good results. https://t.co/0GIsI6DvZM #breastcancer ()

Do I Need Chemo? Oncotype Testing Explained @jrgralow explains the different prognostic tests available, what they really mean and why your recurrence score may indicate something different than you thought: https://t.co/UVOqbiAsDk #bcsm #breastcancer ()

Expensive molecular tests like OncoTypeDx (breast cancer) have been effectively marketed without and decent studies evaluating how much (if) prediction improves when added to optimal models using standard variables (e.g. https://t.co/QEQ2wy56rA). CoI declaration - .... ()

Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early bre… https://t.co/Zn2BA9IrgB @jsparano @RimapatelMD @MelanieKierMD @IcahnMountSinai #breastcancer ()

The results of this study show no agreement between IHC-measured Ki67 using the International Ki67 Working Group prognostic groups & Oncotype DX Recurrence Score in patients with early #BreastCancer. https://t.co/LLFKDp9QNU @TischCancer @RimapatelMD @jsparano @OncoAlert ()

Reviewing breast CA section now and at first I was like, ugh can’t they just make table of yes/no adjuvant chemo based on nodes/menopause/Oncotype instead of mentioning each trial? Then I realized #BCsm docs probably say the exact same thing about every Tx decision in myeloma 🤣 ()

Drs. @VeredStearns & Raquel Nunes discuss the role of Oncotype DX and MammaPrint, two validated gene signatures that are commonly used for premenopausal women with HR-positive, HER2-negative #BreastCancer. https://t.co/8j5kUVKqun #ASCODailyNews #bcsm ()

Dr. Julia Giordano and co-authors (@OKantorMD, @DrHBurstein, @stolaney1, @TariKingMD, @DrBOvermoyer and others) shared their #ASCO22 poster titled: Is there a role for the oncotype DX breast recurrence score genomic assay in estrogen receptor-low positive breast cancer? ()

Agree or disagree: In *general*, for a 65 yo healthy pt with a T2N1 2.1 cm Er pos, her2 neg breast ca, oncotypeDx=27 the appropriate adjuvant chemo reg is ddAC->T or equivalent, rather than TC×4 Discuss if inclined @tmprowell @RitaNandaMD @olwenhahn @NicoleKuderer ()

New #BreastCancer research from our chair, Ruth O'Regan, M.D.: Oncotype DX should be considered for high grade ER-positive cancers less than 1cm. #URochesterResearch @oreganruth  https://t.co/5U7uyjErca ()

The late Aron Goldhirsch maintained, 20 years ago and before OncotypeDX testing, that there was essentially no chemotherapy benefit for lobular breast cancer. He was essentially right. @curijoey (@DrHBurstein)

Comparison of the Distribution of Oncotype Dx Recurrence Scores Between Invasive Ductal Carcinoma and Invasive Lobular Carcinoma of the Breast @SidYadavMD https://t.co/b5mZbl9Eyh (@BTFjournal)

In ER+ breast cancer (less deadly than acute leukemia), biomarkers for standard of care chemo (Oncotype Dx) the community rightfully decided on a sensitive cutpoint (avoiding false- 👉avoid missing pts who may benefit from chemo). But here chemo rarely fatal w appropriate supponc (@NicoleKuderer)

But when i think about innovation i think about something similar to OncotypeDx for radiotherapy of breast cancer...something through which it's possible to optimize TCP/NTCP for every single patient...this is innovation ( revolution). Of course also optimization has some merit😉 (@CTuscanoMD)

Panel recommendations for premenopausal women with ER+ HER2- breast cancers by nodal status and OncotypeDX score #StGallen 2021 @Annals_Oncology @OncoAlert (@DrHBurstein)

I think the editorial sums up the data very nicely. This is the same level of data that Oncotype Dx had for breast cancer for NSABP trials. As the editorial says this is level 1 data for biomarker studies (@DrSpratticus)

Thoughtful editorial by @jsparano & @OtisBrawley accompanies analysis showing racial diffs in prognostic accuracy of Oncotype Recurrence Score (RS) in ER+ @BreastCancer, discusses data & potential explanations, & ways to address https://t.co/05UZeejciM #BCSM (@JAMAOnc)

Our finding suggests #OncotypeDX increased the level of agreement and led to a decrease in the use of adjuvant #chemotherapy compared to pre #OncotypeDX recommendations. 30% were node positive #breastcancer #bcsm https://t.co/V56pVgMUEC (@atlal_abusanad)

Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer–Specific Mortality Among US Women ⁦⁦@gregcalip⁩ ⁦@UICancerCenter⁩ ⁦@DamianoRondell1⁩ https://t.co/vdfMOXuI5f (@KarenSweiss)

"Thoughtful editorial by @jsparano & @OtisBrawley accompanies analysis showing racial diffs in prognostic accuracy of Oncotype Recurrence Score (RS) in ER+ @BreastCancer, discusses data & potential explanations, & ways to address https://t.co/pkpHBAMpkC #BCSM" (@JAMAOnc)

Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early #breastcancer | ⁦@ASCO_pubs⁩ ⁦@SABCSSanAntonio⁩ ⁦@OncoAlert⁩ ⁦@jsparano⁩ https://t.co/MerQIPhN2X (@jamecancerdoc)

ADAPT data show excellent outcomes for women with 1-3+ LN and ODX scores < 11 without chemo. Supports interpretation of RxPonder that benefit is related to OFS.@SABCSSanAntonio #SABCS20 (@DrHBurstein)